1. Pink Sheet
  2. >>Biosimilars & Generics
  3. >>Biosimilars

Pfizer’s Retacrit Finally Clears US FDA, But Biosimilar’s Launch Date Is Still Unclear

 
• By Sue Sutter

First biosimilar of Epogen/Procrit might launch this year, but timing of market entry will depend on many factors, including ongoing patent litigation with Amgen in Delaware federal court.

FDA Approved typed words on a vintage typewriter

With US FDA approval finally in hand, Pfizer Inc. is working toward launching Retacrit (epoetin alfa-epbx), its biosimilar to Amgen Inc.’s Epogen/Johnson & Johnson’s Procrit (epoetin alfa), this year.

Pfizer is “moving ahead with the preparation of our launch plans for 2018,” although launch timing “will ultimately depend on a number of

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Biosimilars & Generics